Cargando…

Novel SGLT2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects

The antisense compound ISIS 388626 selectively inhibits renal glucose reabsorption by inhibiting the sodium–glucose cotransporter‐2 (SGLT2) mRNA expression. It is developed as an insulin‐independent treatment approach for type 2 diabetes mellitus (T2DM). The safety, tolerability, pharmacokinetics, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Meer, Leonie, van Dongen, Marloes, Moerland, Matthijs, de Kam, Marieke, Cohen, Adam, Burggraaf, Jacobus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461644/ https://www.ncbi.nlm.nih.gov/pubmed/28596840 http://dx.doi.org/10.1002/prp2.292

Ejemplares similares

Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

A randomized controlled trial with a delayed‐type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man
por: Saghari, Mahdi, et al.
Publicado: (2020)

The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial
por: Grievink, Hendrika W., et al.
Publicado: (2020)

Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals
por: Reijers, Joannes A. A., et al.
Publicado: (2017)

Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?
por: in ‘t Veld, Aliede E., et al.
Publicado: (2019)

Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics
por: in ’t Veld, Aliede E., et al.
Publicado: (2022)

Immune Monitoring of Mycophenolate Mofetil Activity in Healthy Volunteers Using Ex Vivo T Cell Function Assays
por: in ’t Veld, Aliede E., et al.
Publicado: (2023)

Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals
por: Reijers, Joannes A. A., et al.
Publicado: (2019)

Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
por: Radanovic, Igor, et al.
Publicado: (2022)

Stability analysis of clustering of Norris’ visual analogue scale: Applying the consensus clustering approach
por: Guan, Zheng, et al.
Publicado: (2021)

Evaluation of the EndoPAT as a Tool to Assess Endothelial Function
por: Moerland, M., et al.
Publicado: (2012)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

Whole blood assay as a model for in vitro evaluation of inflammasome activation and subsequent caspase-mediated interleukin-1 beta release
por: Tran, Thi Anh Thu, et al.
Publicado: (2019)

Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers
por: Buters, Thomas P., et al.
Publicado: (2022)

MAN1B1 Deficiency: An Unexpected CDG-II
por: Rymen, Daisy, et al.
Publicado: (2013)

Comprehensive, Multimodal Characterization of an Imiquimod‐Induced Human Skin Inflammation Model for Drug Development
por: van der Kolk, Tessa, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds
por: van Esdonk, Michiel J., et al.
Publicado: (2017)

Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
por: Kaneto, Hideaki, et al.
Publicado: (2021)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020)

Mathematical modeling of the glucagon challenge test
por: Masroor, Saeed, et al.
Publicado: (2019)

Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes
por: Heuberger, Jules A. A. C., et al.
Publicado: (2020)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition
por: Ng, Wai-Lung, et al.
Publicado: (2017)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds
por: Nan, Yuchen, et al.
Publicado: (2018)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Vrouwe, Josephina P. M., et al.
Publicado: (2021)

Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial
por: Jacobse, Justin, et al.
Publicado: (2021)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers
por: Buters, Thomas P., et al.
Publicado: (2021)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

Unexpected Acute Hyperglycemia Following Pre-Surgical Discontinuation of SGLT2 Inhibitors in a Type 1 Diabetic Patient
por: Tsujimoto, Yuki, et al.
Publicado: (2023)

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology
por: Rissmann, Robert, et al.
Publicado: (2020)

OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005
por: Saghari, Mahdi, et al.
Publicado: (2022)

A young man with persistent dyspepsia: the unexpected virtue of proton-pump inhibitors
por: Paolo, Fraticelli, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dojqsfa8j55vctsude3sath74l